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Tumor necrosis factor (TNF)' is a 17,500-M, polypeptide produced by mac-
rophages and related monocyte-like cell lines that induces hemorrhagic necrosis
ofmurine sarcomas (1). In vitro, TNF also binds with high affinity (Kd 200-610
pM ; number of binding cites per cell [B..] 2,200-7,500) to a variety of cell lines
(2-4), affects proliferation of normal and transformed cells (5), and modulates
-the hemostatic properties of cultured endothelial cells (EC) (6, 7) . TNF also
stimulates production of IL-1 in both resting macrophages (8) and EC (9, 10) .
IL-1 promotes growth of fibroblasts and mitogen-stimulated lymphocytes, but
not vascular smooth muscle cells (SMC) grown under low-serum conditions (11) .
Recent evidence, however, suggests that IL-1 promotes EC production ofa factor
that stimulates growth of bovine aortic SMC (12) . EC constitutively produce
both platelet-derived growth factor (PDGF) (13-16), and EC-derived growth
factor (17). Release of PDGF, in particular, is significantly enhanced by agents
that stimulate production of IL-1 such as phorbol esters and endotoxin (18), and
also by coagulation factor Xa (19) and thrombin (20) .
The present study was designed to examine the effect of TNF on EC produc-
tion ofSMC mitogenic activity . EC challenged withTNF released SMC mitogenic
activity in a saturable, concentration- and time-dependent fashion . Release of
SMC mitogenic activity was totally inhibited by antibody to platelet PDGF .
Similar mitogenic activity was also released upon stimulation of EC with IL-1 .
The stimulatory effect of TNF was largely abrogated by pretreatment of cells
with actinomycin D, and Northern blot analysis revealed a 2.5-fold increase in c-
sis hybridizable RNA after stimulation with TNF. Thus, we have demonstrated
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that TNF stimulates release from EC of PDGF-like molecules (PDGF,). This
effect may be partially mediated by EC release of autocrine IL-1, or may involve
other mediators.
Materials and Methods
Endothelial Cell Culture.
￿
Human umbilical vein EC were cultured according to pub-
lished methods (21-24). Briefly, early passage (P2-P5) EC were grown to confluency on
gelatin-coated 24-well tissue culture plates (Falcon Labware, Oxnard, CA). The cells were
plated at a density of 4 x 104 cells per well, reached confluence by 48-72 h, and were
used within 3-5 d of plating. Culture medium consisted of Medium 199 (Grand Island
Biological Co., Grand Island, NY) containing 50 U/ml penicillin, 50 P.g/ml streptomycin,
2.5 tag/ml fungizone, 2.0 mM t.-glutamine, 20 wg/ml endothelial cell growth factor (Meloy
Laboratories, Inc., Springfield, VA), 90 gg/ml porcine intestinal mucosa heparin (170
USP units/mg), and 20% pooled human serum. For cell passage, monolayers were washed
with Hepes-buffered saline, and incubated for 5 min in the same containing 0.05% Type
I collagenase, 0.01% EDTA, and 0 .25% BSA at 37°C. After addition of an equal volume
of serum-containing medium, the cells were washed once, resuspended, and plated. Cells
were grown at 37°C in a humidified atmosphere with flowing 5% C02/95% air.
SMCCulture.
￿
SMC were cultured from bovine arteries by the procedures of Ross (25)
and Hajjar et al. (26). Briefly, early passage (P2-P6) SMC were grown from explants on
Falconware in MEM (Gibco Laboratories, Grand Island, NY) containing 50 U/ml penicil-
lin, 50 ug/ml gentamicin, 2.5 lAg/ml fungizone, 2.0 MM L-glutamine, and 20% FCS (heat-
inactivated). For routine cell passage, cultures were washed, removed from the plates,
and replated (25, 26). Cells were propagated in a humidified atmosphere containing 5%
C02/95% air at 37°C .
Treatment of Endothelial Cells with TNF and IL-1.
￿
Confluent EC were washed twice
with PC-1 medium (Ventrex Laboratories Inc., Portland, ME), and treated for various
periods of time (2-24 h) with PC-1 containing various concentrations (0-3.0 nM) of
recombinant human TNF (Genentech, South San Francisco, CA) or recombinant IL-10.
IL-1/3 was a gift from Dr. Charles Dinarello, Tufts University School of Medicine, Boston,
MA. The resulting postculture medium was harvested and added immediately to semicon-
fluent bovine SMC previously washed twice with PBS . In some experiments, polymyxin
B (10,ug/ml; Sigma Chemical Co., St. Louis, MO) was added to exclude possible endotoxin
effects (27).
Treatment of Endothelial Cells with Actinomycin D.
￿
Cells were preincubated with 0.16
tM actinomycin D (Sigma Chemical Co.) for 30 or 120 min (28), and then washed three
times with PC-1 before treatment with TNF as described above.
Mitogenesis Assay. Mitogenic activity of arterial SMC was measured as described
extensively by DiCorleto and Bowen-Pope (29). All samples were assayed in quadruplicate;
standard deviations averaged 10% of the mean.
Lactate Dehydrogenase (LDH)-release Assay.
￿
LDH activity in postculture medium was
measured using a commercially available kit (Sigma LD-L; Sigma Chemical Co.), according
to the method of Wacker et al. (30). Release of LDH from EC was determined for
postculture medium samples after treatment of cells with PC-1 alone, PC-1 plus TNF, or
sonication at 4°C (Heat Systems-Ultrasonics, Inc., Farmingdale, NY; power 4, duty cycle
40%, 10-s continuous pulse). Linearity of the assay was verified using normal and high
LDH standards provided by the manufacturer.
Immunoinhibition Studies.
￿
Postculture medium from TNF-stimulated cells was prein-
cubated with rabbit anti-human platelet PDGF. This antibody, a gift from Dr. Thomas
Deuel, Washington University, St. Louis, MO, was obtained from rabbits immunized with
purified human PDGF and judged monospecific in immunodiffusion analyses against
platelet lysates, serum, and plasma (31). Additional samples of postculture medium were
preincubated with anti-EC antibody (24), or nonimmune goat serum (CooperBiomedical,
Inc., Malvern, PA) as described in the figure legends. In some experiments, EC were
stimulated with TNF in the presence of various antibodies, including rabbit anti-recom-FIGURE 1 . Effect of various
doses of TNF and IL-1 on the
release of mitogenic activity by
EC. EC, grown to confluency in
24-well plates, were washed twice
in PC-1 and incubated in PC-1
containing increasing amounts of
rTNF or IL-1 for 18 h at 37°C.
EC postculture medium was then
harvested and applied directly
(0.8 ml/well) to washed semicon-
fluent SMC. SMC were incubated
0.074 0.148 0.222
￿
for 18 h (37°C) in the presence
TNF (nM)
￿
IL-1 (nM)
￿
of ['H]thymidine (sp act, 18 .2
Ci/mM; I IACi/10,000 cells;
50,000 cells/well). The SMC were then washed, trypsinized, and the TCA-precipitable material was
counted as described in Materials and Methods. (A) Effect of TNF. Each point represents the mean
of five samples stimulated with various concentrations of TNF (0.013-3.18 nM). All samples were
normalized for cell number. Control cells represented incorporation of 65,921 ± 6,738 cpm ± SE of
['H]thymidine per well. (B) Effect of IL-1 . Each bar represents the mean of five samples stimulated
with three different concentrations of IL-1 (0.074, 0.148, and 0.222 nM). Results are expressed as
percent increase over control (0% or 30,241 ± 9,450 cpm/well t SE).
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binant IL-lß, a gift from Dr. Charles Dinarello, Tufts University School of Medicine,
Boston, MA. This antibody contained a gamma globulin concentration of 16 mg/ml and
neutralized IL-Iß at a concentration of 1 :100 to 1 :1,000. It was inactive against IL-la
(Dinarello, C., personal communication).
Northern Blot Analysis.
￿
Human umbilical vein EC (P,) were grown to confluency in
75-cm' flasks (Falcon Labware). The cells were washed twice with PC-1, and then treated
with either TNF (25 ng/ml in PC-1) or PC-1 alone and incubated for 18 h at 37°C in a
5% C02 humidified incubator. The cell monolayers were then washed three times with
Hepes-buffered saline and detached with 0 .05% Type I collagenase, 0.01% EDTA, and
0.25% BSA (5 min, 37 ° C). Cells in the resulting single-cell suspension (total number of
EC ^-22.5 X 106, treated and control) were washed three times with PBS. Total cellular
RNA was prepared from these pellets by extraction in 4 M guanidium isothiocyanate, 5
mM sodium citrate, 0.1 M 2-ME, and 0.5% sarkosyl followed by centrifugation through
CsCI (32, 33). Total cellular RNA (14 wg) from TNF-treated or control cells was first
denatured with formaldehyde, electrophoresed in a 1 % agarose gel, and then transferred
to nitrocellulose filters (33). In addition, 30 Ag of total cellular RNA isolated from the
human melanoma cell line A875 was electrophoresed and transferred. Hybridization was
carried out at 42'C for 15 h in 50% formamide, I X Denhart's solution, 100 tag/ml salmon
sperm DNA, 10% Dextran sulfate, 0.75 M NaCl, 0.075 M sodium citrate, 0.05 M
NaH2PO4 H2O, 5 mM EDTA, pH 7.4, using a '2P-labeled c-sis DNA probe nick-translated
to a sp act of 3.9 X 107 dpm/Pg. The c-sis probe used was a 1 .6-kb Barn HI human
genomic fragment designated PI 335 and was generously provided by F. Wong-Staal and
R. Gallo, National Institutes of Health, Bethesda, MD (34). The filter was then washed in
0.3 M NaCl, 0.03 M sodium citrate, 0.1% SDS, pH 7.0, at 68 ° C and autoradiograms
were obtained after 5, 14, and 24 h of exposure. The relative intensity of the sis probe
hybridizing band was estimated by laser densitometric scanning of the autoradiograms.
Results
Incubation of SMC with postculture medium from EC stimulated with various
doses of TNF for 18 h led to a dose-dependent and saturable increase in
incorporation of ['H]thymidine into SMC (Fig. I A). This stimulatory effect
became maximal at a TNF dose of ^-10 ng/ml (570 pM) where the rate of SMC
proliferation was increased 90% over controls. Half-maximal stimulation was
reached at a TNF dose of -2 ng/ml, resulting in an EC50 for this interaction of23 8
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FIGURE 2.
￿
Time course of appearance of
mitogenic activity in postculture medium
from TNF-stimulated EC. EC were stimu-
lated with TNF (0.08 nM) for various pe-
riods of time as indicated on the abscissa.
EC postculture medium was assayed for mi-
togenic activity as described in the legend
to Fig. 1. Each point represents the mean
of quadruplicate samples. Results are ex-
pressed as percentincrease overcontrol (0%
or 82,451 ± 7,601 cpm/well t SE).
114 pM. This increase in [sH]thymidine incorporation was paralleledby cellular
proliferation as cell counts rose from a mean of 52,000 ± 4,004 (SE, n = 4) to a
mean of 147,500 ± 14,362 (SE, n = 4) after 18 h of treatment with TNF (10
ng/ml). A similar effect was achieved by stimulating EC with IL-1 (60-250 pM),
which resulted in a 100% increase in the SMC proliferation rate (Fig. 1 B) . These
results suggest a high affinity interaction between these monokines and the
endothelial cell involving one or more specific binding sites.
The time course for the production of mitogenic activity by TNF stimulation
of EC is shown in Fig. 2. A slight (34 .7-43 .5%) increase in mitogenic activity
was detectable after 2-6 h of TNF stimulation. This was followed by a major
peak of activity at 15 h, which represented a tripling of baseline activity and
persisted for up to 24 h . Thus, the initial small increase in mitogenic activity
might reflect constitutive release of PDGFc while it appears that an initial lag
period may be required for full expression of the stimulatory effect of TNF.
To determine whether the mitogenic effect of EC postculture medium could
be attributed to passive transfer of TNF, the direct effect of TNF on SMC
mitogenesis was studied. Only a slight increase in mitogenesis (17%) was observed
at concentrations of 53.2 ng/ml (3.0 nM). This dose was ^-10 times that used
routinely to stimulate EC that responded with a 100-300% increase in SMC
proliferation. Postculture medium from nonstimulated EC showed minimal
enhancement of [sH]thymidine incorporation into dividing SMC (32 ± 6%, SE),
even when added to SMC in the presence of TNF (10 ng/ml) (34.4 ± 4%, SE).
IL-1 alone had no mitogenic effect when added directly to SMC . In addition,
polymyxin B had no effect on SMC mitogenesis in response to postculture
medium from TNF-stimulated EC .
Immunoinhibition studies were carried out to examine the mechanism by
which postculture medium from TNF-stimulated EC promoted SMC prolifera-
tion (Fig. 3). Postculture medium from nonstimulated EC enhanced SMC mito-
genesis by 29 .4%, while postculture medium from TNF-stimulated cells pro-
duced a 96.8% increase in mitogenic activity. When TNF-stimulated postculture
medium was preincubated with anti-platelet PDGF, its mitogenic activity was
completely abrogated (0%) and cellular proliferation returned to the baseline
level. Antibody to intact EC and nonimmune goat serum failed to significantly
inhibit mitogenic activity (94.9 and 123.3% of control, respectively) produced0
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FIGURE 3.
￿
Immunoinhibition ofmitogenic activ-
ity by anti-PDGF,. Semiconfluent SMC were incu-
bated with preculture medium (40,040 t 1,965
cpm/well t SE) (A) or postculture medium from
nonstimulated EC (B) or from EC stimulated with
TNF (1 .43 nM) (C-F). Postculture medium from
stimulated EC was pretreated with either anti-
platelet PDGF (D), anti-endothelial cell antiserum
(E), or nonimmune goat serum (F) at dilutions of
1:200 for 1 h at 37°C. SMC mitogenesis was
measured by uptake of ['H]thymidineas described
in the legend to Fig. 1. Each bar represents the
mean of four samplesnormalized for cell number.
FIGURE 4.
￿
Effect ofanti-IL-1 on TNFin-
duction of mitogenic activity. Semicon-
fluent SMC were incubated (37°C, 18 h)
with preculture medium (231,212 t 27,638
cpm/well t SE) (A), postculture medium
from nonstimulated EC (B), postculture me-
dium from EC stimulated with TNF (0.40
nM) alone (C) or TNF in the presence of
either anti-IL-1 (D)or anti-EC(E)antibody.
Allantisera were diluted 1:200 (vol/vol) in
serum-free medium and used immediately.
SMC mitogenesis was measured as de-
scribed in the legend to Fig. 1. Each bar
represents the mean of four samples nor-
malized forcell number.
by TNF stimulation. In similar experiments, mitogenic activity in postculture
medium from nontreated EC was partially (68.8%) inhibited by treatment with
anti-PDGF at a dilution of 1:200 (49,108 ± 17,518 cpm/well ± SE, n = 4) as
compared with treatment without antibody (157,465 ± 11,919 cpm/well ± SE,
n = 4) or with control (anti-EC) antibody (103,530 ± 23,660 cpm/well ± SE,
n = 4). Anti-PDGF alsoblocked the mitogenicactivity inducedby IL-1-stimulated
EC (data not shown). Thus, PDGF-like molecules appeared to play a major role
in stimulating SMC proliferation.
Treatment of EC with TNF in the presence of anti-IL-1 enhanced SMC
mitogenic activity to 58.9% (± 2.2%, SE, n = 4) over control as compared with
a 97.4% (± 4.1%, SE, n = 4) increase over control for TNF alone (Fig. 4). When
EC were treated with TNF in the presence ofan irrelevant antibody (anti-EC),
the SMC proliferative effect in the resulting postculture medium represented an
80.9% (± 7.6%, SE, n = 3) increase over control. These results suggested that
elaboration ofSMC proliferative activity by TNF-stimulated EC may have been
partially mediated byTNF-inducedsecretion ofautocrine IL-I by theendothelial
cell.
The effect ofinhibition of RNA synthesis on production ofmitogenic activity
by TNF-stimulated EC was also examined. Preincubation of EC with 0.16 JIM
actinomycin D for 120 min blocked all but 26.3% ofmitogenic activity released
by TNF-treated EC, while after 30 min of actinomycin D blockade, release of240
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TABLE I
Effect ofActinomycinD on TNF-induced PDGF, Release by EC
EC were prepared as described in the legend to Fig. 1 . After two washes with
PC-1, EC monolayers were preincubated with actinomycin D (0.16 UM in PC-1)
for 30 min or 120min as indicated . Culture medium wasthen removed, and the
cells were washed twice with PC-1, and incubated with TNF (0.08 nM) in PC-1
or PC-I alone for 18 h . The resulting EC postculturemedium (ECCM) was then
added to proliferating SMC and its mitogenic activity was assessed . Activity is
expressed as [SHjthymidine incorporation (dpm ± SE, n = 4), and as percent
above control (ECCM).
FIGURE 5 . Level of c-sis mRNA in TNF-
treated EQ. . RNA samples were electropho-
resed in 1 °lo agarose in the presence of formal-
dehyde, transferred to nitrocellulose, and then
hybridized with a 'sP-labeled c-sis DNA probe .
Lanes are (A) 30 wg total cellular RNA ex-
tracted from human melanoma A935 cells, (B)
14 kg total cellularRNAfrom control EC, and
(C) 14 wg total cellular RNAfrom TNF-treated
EC . Molecular weight markersare indicatedon
the left as the position ofmigration of 18S (1.9
kb)and 28S (5 .1 kb) species .
mitogenic activity by TNF was 68.0% of control (Table I) . This inhibitory effect
did not reflect cell death or injury since neither exclusion of trypan blue nor
release ofLDH in actinomycin D-treated samples was elevated over untreated
controls (data not shown) . In addition, Northern blot analysis was carried out .
Both TNF and control EC showed a strong band at ^-3.5-3.7 kb hybridizing
with the specific sis probe (Fig . 5) . Melanoma cells did not express the sis gene .
Densitometric analysis revealed a 2.5-fold increased expression of the sis gene
Culture condition Mitogenic activity
Amount
above
control
ECCM 30,264 t 5,719 0
ECCM (TNF) 58,974 t 9,803 94.9
ECCM (TNF, Act D, 30') 49,797 ± 3,659 64.6
ECCM (TNF, ActD, 120') 37,824 t 3,818 25.0HA,IJAR ET AL.
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by the TNF-treated cells compared with control. In addition, a minor band at
-4.3 kb was also noted in the TNF-treated samples; the significance of this band
is currently unknown.
Discussion
The present data indicate for the first time that recombinant human TNF
stimulates release of an EC factor that is mitogenic for bovine SMCs and that is
completely neutralized by antibody to platelet PDGF. Elaboration of PDGFc
appears to be dose related and saturable, with half-maximal stimulation occurring
at ^-2 ng/ml (-114 pM) TNF, suggesting the presence of discrete, high-affinity
binding sites (Fig. 1 A) for this peptide. In agreement with the literature (12), a
similar effect was achieved by stimulation with rIL-1 at 1-4 ng/ml (60-240 pM)
(Fig. 1 B).
The mitogenic activity in postculture medium from TNF-stimulated EC can
be completely neutralized by antibody to platelet PDGF (Fig. 3). Thus, PDGF
are apparently released by EC in response to TNF challenge. Although freshly
isolated adult rat SMC produce PDGF during their first few days in culture (35,
36), the rate of production of PDGF declines upon further subculture, suggest-
ing that the mitogenic effect in these passaged cells is not due to autocrine
stimulation by endogenous PDGF from SMC. TNF alone at doses up to 53
ng/ml had no significant mitogenic effect on bovine SMC. Therefore, the
observed proliferation cannot be attributed to passive transfer of TNF in the
postculture medium.
Time-course studies (Fig. 2) suggested that the major release of mitogenic
activity occurs only after 6 h of TNF stimulation . Earlier time points showed
only a slight (35-45%) increase in activity, which probably reflects constitutive
production of PDGF (16, 29). This finding raises the question of whether a
series of intermediate events might be required before release of PDGF in
response to TNF occurs. Upon stimulation with thrombin (20), human EC
released PDGF in an approximately linear fashion for up to 24 h; significant
PDGF release was first detected at 1 .5 h . Bovine EC elaborate PDGF after
challenge with factor Xa in an apparently biphasic fashion over 16 h, with first
appearance of PDGF within as earlyas 2 min (19). These various release patterns
may reflect differential modes of agonist processing by the endothelial cell, and
suggest that these agents may act through different mechanisms.
Release of PDGF from human umbilical vein EC was associated with PDGF-
specific RNA synthesis since c-sis hybridizable RNA was increased 2.5-fold after
TNF stimulation of EC (Fig. 5), and since release of proliferative activity was
substantially inhibited by preincubating cells with actinomycin D (Table I). In
cultured adipocytes, TNF is known to downmodulate the activity of differentia-
tion-specific enzymes such as lipoprotein lipase by acting at the level of transcrip-
tion (37-40). Similarly, in dermal fibroblasts and synovial cells, TNF enhances
production of prostaglandin E2 and collagenase (41). In addition, the recently
reported effects of TNF on the endothelial cell, such as induction of IL-1
secretion (9, 10), increase in tissue factor activity (6, 7), and promotion of
neutrophil adhesion (42) also appear to reflect new synthesis of mRNA and
hence protein . It now appears that the observed release of PDGF from EC may242
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represent an additional example of gene expression that is controlled by this
inflammatory mediator.
TNF is known to bind to human umbilical vein EC (apparent Kd -125 pM)
and to augment release of IL-1 through a protein synthesis-dependent mecha-
nism (9, 10). Immunoinhibition studies reported herein (Fig. 4) indicate that
TNF-induced release of PDGF, by EC was partially blunted by antibody to IL-
1, suggesting a role for this monokine. On the other hand, the release of
mitogenic activity was also clearly associated with a several-fold increase in
synthesis ofmRNA specific for PDGF,. Therefore, it appears that PDGF, release
may reflect a dual mechanism, involving both secretion ofautocrine IL-1 and de
novo synthesis of PDGF,.
In the endothelial cell, TNF is an important inducer of IL-1 secretion (9, 10).
IL-1, in turn, appears to feed back upon the cell, thereby modulating its role in
hemostasis by promoting its procoagulant properties (43, 44), and by inducing
synthesis of plasminogen activator-inhibitor (45-47). In addition, both mono-
kines promote leukocyte adhesion to endothelial monolayers (42, 48). Our data
suggest an additional role for TNF, namely release ofEC-derived PDGF,. Thus,
through a series ofcell-cell interactions, the release of key monokines may play
an important role in vessel wall biology, not only by favoring the maintenance
of fibrin, but also by modulating vascular tone (49) and SMC proliferation. In
this way, TNF and IL-1 may play a role in both normal and abnormal responses
to vascular inflammation, wound healing, and atherogenesis.
Summary
Platelet-derived growth factor (PDGF) is a 30,000-Mr glycoprotein that is
chemotactic and mitogenic for vascular smooth muscle cells (SMC). It is also a
potent vasoconstrictor. In the present study, we found that the macrophage-
derivedpolypeptide, tumor necrosis factor (TNF), releases a factor from human
umbilical vein endothelial cells (EC) that is mitogenic for SMC. Postculture
medium from TNF-stimulated EC induced a 90% increase in mitogenesis as
compared with controls. This effect was half-maximal at a TNF dose of 114 pM,
reflected a 2.5-fold increase in PDGF-specific mRNA synthesis, and peaked at
15 h of TNF stimulation. Mitogenic activity was completely abrogated by
preincubation ofpostculture medium with antibody to platelet PDGF. Stimula-
tion ofEC with IL-1 (60-240 pM) led to the release ofsimilar mitogenicactivity.
Thus, in addition to its effects on the hemostatic and adhesive properties ofEC,
TNF also promotes release ofPDGF, which may serve to modulate proliferation
ofvascular SMC during wound healing, inflammation, and atherogenesis.
We gratefully acknowledge the excellent technical assistance of Nancy Hamel andJohn
Shuman .
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